Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-04-19
2005-04-19
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S137100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S154100, C424S184100
Reexamination Certificate
active
06881406
ABSTRACT:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra−, and integrin α4β7−, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.
REFERENCES:
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5932703 (1999-08-01), Godiska et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6245332 (2001-06-01), Butcher et al.
patent: 6488930 (2002-12-01), Wu et al.
patent: 20020098545 (2002-07-01), Li et al.
patent: 0 860 446 (1998-08-01), None
patent: WO 9623068 (1996-08-01), None
patent: WO 9640923 (1996-12-01), None
patent: WO 9844953 (1998-10-01), None
patent: WO 0042074 (2000-07-01), None
Chuntharapai et al. (1997) Methods in Enzymology, vol. 288, pp. 15-27.*
Reiss et al. J. Exp. Med. 2001;194(10):1531-1547.*
Biedermann et al. Eur. J. Immunol. 2002; 32:3171-3180.*
Huang Pharmacol. Therapeutics 2000 86:201-215.*
Schwarz et al. Cur. Opin. Chem. Biol. 1999; 3:407-417.*
Gerard et al. Nature Immunol. 2001;2:108-115.*
Branch TIBS 1998; 23:45-50.*
Heath et al. J. Clin. Invest. 1997; 99:178-184.*
Bendig Methods:A Companion to Meth. Enzymol. 1995; 8:83-93.*
Baggiolini, et al. Chemokines and Leukocyte Traffic,:Nature, (Apr. 9, 1998) vol. 392-565-568.
Baggiolini et al. “Blocking Chemokine Receptors,”J. Exp. Med.,(Oct. 20, 1997) vol. 186(8):1189-1191.
Campbell, James J. et al. “6-C-kine (SLC), A Lymphocyte Adhesion-Triggering Chemokine Expressed by High Endothelium, Is an Against for the MIP-3beta Receptor CCR7,”Journal of Cell Biology, (May 18, 1998) vol 141(4):1053-1059.
Bonecchi, et. al., “Differential Expression Of Chemokine Receptors And Chemotactic Responsiveness Of Type 1T Helper Cells (Th1s) and Th2s,”J. Exp. Med.(Jan. 5, 1998) vol. 187, No. (1): 129-134.
Durig, et. al.,“Expression Of Macrophage Inflammatory Protein-1α Receptors In Human CD34+Hematopoietic Cells And Their Modulation By Tumor Necrosis Factor-α And Interferon-γ,”Blood(Nov. 1, 1998) vol. 92, No. (9): 3073-3081.
Dutton et al. “T Cell Memory,”Ann. Rev. Immunol., (1998) vol. 16:201-23.
Fuhlbrigge et al. “Cutaneous Lymphocyte Antigen is a Sepcialized Form of PSGL-1 Expressed on Skin-Homing T Cells,”Nature, (Oct. 30, 1997) vol. 389:978-981.
Imai, et. al., “Macrophage-Derived Chemokine Is A Functional Ligand For The CC Chemokine Receptors 4*,”J. Biol. Chem.(Jan. 16, 1998) vol. 273, No. (1) : 1764-1768.
Imai, et. al., “The T Cell-Directed CC Chemokine TARC Is A Highly Specific Biological Ligand For CC Chemokine Receptor 4*,”J. Biol. Chem.(Jun. 6, 1997) vol. 272, No. (23): 15036-15042.
Meyer, et. al., “Cloning And Characterization Of A Novel Murine Macrophage Inflammatory Protein-1α Receptor*,”J. Biol. Chem., (Jun. 14, 1996) vol. 271, No. (24): 14445-14451.
Power, et. al., “Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor cDNA From A Human Basophilic Cell Line,”J. Biol. Chem., (Aug. 18, 1995) vol. 270, No. (33): 19495-19500.
Tangemann et al.,The Journal of Immunology, (1998) vol. 161:6330-6337.
Teraki et al.,Immunolgy, (1997), vol. 159:6018-6029.
Catalog of Santa Cruz Biotechnology, Inc., Research Antibodies 97/98: 319-320.
Youn, et. al., “Molecular Cloning And Characterization Of A cDNA, CHEMR1, Encoding A Chemokine Receptor With Homology To The Human C-C Chemokine Receptor, CCR-4,” ABlood, (Jun. 15, 1997) vol. 89, No. (12):4448-4460.
Genebank Accession No. X85740, Locus HSCCCR3, “H. Sapiens mRNA for C-C Chemokine Receptor-4” (1996).
Genebank Accession No. X94151, Locus MMMIPIA2, “M. Musculus mRNA for MIP-1 Alpha Receptor 2” (1996).
Heinemann et al., Basophil Responses to Chemokines are Regulated by Both Sequential and Cooperative Receptor Signaling, The Journal of Immunology, 2000, p. 2224-7223.
Imai et al., The T Cell-Directed CC Chemokine Tarc is a Highly Specifica Biological Ligand for CC Chemokine Receptor 4, The Journal of Biological Chemistry, 1997, 272(23): 15036-15042.
Kuna et al., Rantes, A Monocyte and T Lymphocyte Chemotactic Cytokine Releases Histamine From Human Basophils, The Journal of Immunology, 1997, 149(2): 636-642.
Uguccioni et al., High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils Role in Activation by Eotaxin, MCP-4, and Other Chemokines, J. Clin. Invest., 1997, 100(5): 1137-1143.
Andrew et al., STCP-1 (MDC) CC Chemokine Acts Specifically on Chronically Activated TH2 Lymphocytes and is Produced by Monocytes on Stimulation with TH2 Cytokines IL-4 and IL-13, J. of Immunology, 1998, 5027-5038.
Campbell et al., The Chemokine Receptor CCR4 in Vascular Recognition by Cutaneous but not Intestinal Memory T Cells, Nature, 1999, 400: 776-780.
Butcher Eugene C.
Campbell James J.
Rottman James B.
Wu Lijun
Keddie James S.
Mertz Prema
Millennium Pharmaceuticals Inc.
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Modulation of systemic memory T cell trafficking does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of systemic memory T cell trafficking, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of systemic memory T cell trafficking will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373752